← Eichor
Condition: Trastuzumab Emtansine Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Trastuzumab Emtansine

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy
EARLY_Phase 1 · 1 location(s) · Vanderbilt-Ingram Cancer Center · NCT06828588Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea
Phase N/A · 1 location(s) · Seoul National University Hospital · NCT06928818Herombopag Treated T-DM1 Induced Platelet Reduction
Phase 2 · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT07257809Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Canc
Phase 3 · 31 location(s) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharm · NCT07008976Tolerability and Efficacy of Adjuvant T-DM1 in Patients with HER2 Positive Breast Cancer After Incomplete Pathological R
Phase N/A · 1 location(s) · Regina Elena Cancer Institute · NCT06272799Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas
Phase 2 · 13 location(s) · Dana-Farber Cancer Institute · NCT04620187Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease
Phase 2 · 1 location(s) · University Health Network, Toronto · NCT05388149A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer
Phase 3 · 2 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06830889Adjuvant Therapy Choice for Non-pCR HER2 Positive Early Breast Cancer After Neoadjuvant Therapy
Phase N/A · 1 location(s) · Shu Wang · NCT06693037JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer
Phase 3 · 1 location(s) · Shanghai JMT-Bio Inc. · NCT06846437A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
Phase 3 · 70 location(s) · GeneQuantum Healthcare (Suzhou) Co., Ltd. · NCT07673029Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzum
Phase 2 · 152 location(s) · NRG Oncology · NCT05408845ATEMPT 2.0: Adjuvant T-DM1 vs TH
Phase 2 · 53 location(s) · Dana-Farber Cancer Institute · NCT04893109A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumo
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05673928Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer
Phase 2/Phase 3 · 1 location(s) · University of Virginia · NCT05288777DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer
Phase 3 · 1 location(s) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · NCT06313086
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.